9,344 shares of Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) acquired by FDx Advisors Inc.


FDx Advisors Inc. acquired a new position in Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) during the first trimester, HoldingsChannel reports. The fund bought 9,344 shares of the company, valued at around $315,000.

A number of other major investors have also recently increased or reduced their stakes in the company. DAVENPORT & Co LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 28.8% in the 1st quarter. DAVENPORT & Co LLC now owns 16,021 shares of the company worth $540,000 after purchasing 3,587 additional shares in the last quarter. Signaturefd LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 26.4% in the 1st quarter. Signaturefd LLC now owns 2,190 shares of the company worth $74,000 after purchasing an additional 458 shares in the last quarter. Cambiar Investors LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 18.3% in the 1st quarter. Cambiar Investors LLC now owns 1,363,874 shares of the company worth $45,935,000 after purchasing an additional 210,819 shares in the last quarter. GHP Investment Advisors Inc. acquired a new stake in Fresenius Medical Care AG & Co. KGaA in Q1 for approximately $72,000. Finally, Timber Creek Capital Management LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 5.1% in the 1st quarter. Timber Creek Capital Management LLC now owns 198,743 shares of the company worth $6,693,000 after acquiring 9,695 additional shares in the last quarter. 4.73% of the shares are held by hedge funds and other institutional investors.

Changes to analyst ratings

Several research companies have recently weighed in on FMS. JPMorgan Chase & Co. raised its price target on Fresenius Medical Care AG & Co. KGaA from €48.70 ($49.69) to €51.00 ($52.04) and assigned the company a rating “underweight” in a Thursday, May 5, research report. Truist Financial cut its price target on Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating on the stock in a Wednesday, June 22 research report. Jefferies Financial Group upgraded Fresenius Medical Care AG & Co. KGaA from an “underperforming” rating to a “buy” rating and raised its price target for the company from $30.30 to $33.70 in a Monday, June 27 research report. To finish, StockNews.com downgraded Fresenius Medical Care AG & Co. KGaA from a “Strong Buy” rating to a “Buy” rating in a Friday, July 15 research report. One research analyst rated the stock with a sell rating, six gave the company’s stock a hold rating and four gave the company’s stock a buy rating. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $52.51.

Pricing performance of Fresenius Medical Care AG & Co. KGaA

Shares of FMS inventory opened at $19.32 on Friday. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $22.06 and a 12-month high of $41.38. The stock has a market capitalization of $11.32 billion, a price/earnings ratio of 11.04, a P/E/G ratio of 0.95 and a beta of 1.21. The stock has a fifty-day simple moving average of $25.76 and a two-hundred-day simple moving average of $30.24. The company has a current ratio of 1.26, a quick ratio of 0.93 and a debt ratio of 0.51.

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) last reported results on Wednesday, May 4. The company reported earnings per share of $0.38 for the quarter, beating the consensus estimate of $0.30 by $0.08. Fresenius Medical Care AG & Co. KGaA achieved a return on equity of 6.99% and a net margin of 4.91%. The company posted revenue of $5.10 billion in the quarter, compared to $4.97 billion expected by analysts. On average, analysts expect Fresenius Medical Care AG & Co. KGaA to post EPS of 1.82 for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Profile

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Featured articles

Want to see which other hedge funds hold FMS? Visit HoldingsChannel.com for the latest 13F reporting and insider trading for Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating).

Institutional ownership by quarter for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)



Get news and reviews for Fresenius Medical Care AG & Co. KGaA Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com’s free daily email newsletter .